ABUS vs NVCT
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ABUS · Arbutus Biopharma$4.02 ▼ 1.23%
NVCT · Nuvectis Pharma$19.39 ▼ 2.27%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ABUS -5.9%
- NVCT +223.7%
Head to head
| Metric | ABUS | NVCT |
|---|---|---|
| Price | $4.02 | $19.39 |
| Change today | ▼ 1.23% | ▼ 2.27% |
| Market cap | $616.24M | $666.80M |
| Return, 3 months | -22.7% | -18.8% |
| Return, year to date | -16.4% | +156.8% |
| Return, 1 year | -6.7% | +218.9% |
| P/E (TTM) | 3.6 | – |
| P/B | 7.2 | 5.3 |
| P/E percentile vs own 5y | 90th | 22nd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -43.5% | – |
| Net profit growth (YoY) | +863.6% | -303.0% |
| Gross margin | – | – |
| Operating margin | 80.1% | – |
| Net margin | 121.2% | – |
| Return on equity | 269.6% | -67.0% |
| Analyst target vs. price | – | +77.9% |
| Analyst buy share | – | 100% |
| RSI (14) | 46 | 47 |
| 30-day volatility | 45.2% | 78.4% |
| Max drawdown, 1 year | -29.9% | -37.7% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- NVCT is the largest of the group by market value.
- NVCT has returned the most over the past year.
- ABUS has been the calmest stock over the last 30 days.